Jan 22, 2021 08:12 PM (GMT+8) · EqualOcean
Hengrui medicine announced that the company recently received the drug registration certificate of dexmedetomidine hydrochloride and sodium chloride injection approved and issued by the State Food and drug administration. Dexmedetomidine hydrochloride and sodium chloride injection is a relatively selective α 2-adrenoceptor agonist, which is intended to be used for sedation in patients with intubation and mechanical ventilation in intensive care unit, and the continuous infusion time is not more than 24 hours; or for preoperative and / or intraoperative sedation and other procedures in patients without intubation.

This text is a result of machine translation.